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Abstract
Retinoblastoma is a rare malignant tumour of the developing retina with an incidence of 1 in 20,000
live births in all human races. Chemotherapy is used in retinoblastoma as adjuvant therapy to prevent
the growth of metastases and to treat metastatic disease once this has become clinically apparent.
Current regimens are based on empirical drug combinations, and few clinical trials have been
conducted because of the rarity of this tumour. Chemosensitivity testing offers a way of testing a large
number of agents against tumours. The ATP-based chemosensitivity assay (ATP-TCA) has already
helped to design new regimens for melanoma and breast and ovarian cancer. Primary retinoblastoma
tumour material was obtained from 10 eyes, 7 of which contained sufficient viable cells for ATP-TCA.
The results show very high sensitivity to single agents, particularly cisplatin, doxorubicin and vinca
alkaloids. Of the anti-metabolites tested, 5-FU is relatively disappointing (although still active), and
gemcitabine shows considerable activity consistent with a cytotoxic effect. The shape of the inhibition
curves is interesting. There is a plateau effect with the topoisomerase inhibitors and vinblastine, which
is not present with the cisplatin. One tumour was much more resistant than the others tested,
particularly to vinblastine but also to the topoisomerase inhibitors, which failed to achieve complete
kill at any concentration tested, consistent with a multidrug resistance phenotype. Of the combinations
(VAC and VEC), the VAC regimen looks marginally more active in the more resistant of the two
cases tested to date. These data confirm that retinoblastoma is a rapidly growing malignancy that is
very susceptible to cytotoxic drugs of all types. Chemosensitivity testing provides a practical method
of testing new regimens before clinical trials in retinoblastoma patients.
Introduction
Retinoblastoma is the most common primary intraocular tumour in children, with an incidence of 1 in
15,000-20,000 live births (Finger et al. 1999). More than 90% of cases are diagnosed before 5 years of
age, and presentation of retinoblastoma in adults is rare (Biswas et al. 2000).
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Successful treatment of retinoblastoma has traditionally depended on surgery and external beam
radiation therapy, associated with significant short- and long-term morbidity (reviewed in Wilson et al.
2001). Recently, multiple studies have been published reporting initial experiences with an association
of systemic chemotherapy and focal methods as a primary treatment for this type of cancer (Shields
and Shields 1999; Friedman et al. 2000).
Chemotherapy is used in retinoblastoma as adjuvant therapy to control intraocular tumour growth with
or without radiation, to prevent the growth of metastases and to treat metastatic disease once this has
become clinically apparent (Gallie et al. 1996; Kingston et al. 1996; Gunduz et al. 1998). Current
regimens are based on empirical drug combinations derived from neuroblastoma treatments, which
have been found to work (Gobie et al. 1990; Kingston et al. 1996). Few clinical trials have been
conducted because of the rarity of this tumour and the difficulty of funding such trials.
The current regimens in use tend to use the following four drugs:
Carboplatin
Etoposide or doxorubicin
Vincristine
Carboplatin is a less toxic platinum compound than cisplatin but acts similarly by platination of DNA.
The platinum adducts are usually repaired by mismatch repair, deficiency of which is associated with
greater sensitivity to this agent (Brown et al. 1997). Etoposide is a podophyllin inhibitor of
topoisomerase II, an enzyme responsible for unfolding DNA during transcription and replication. It is
associated with an increased risk of leukaemia and is therefore rarely used as a first-line drug for other
tumour types (Felix 1998). Doxorubicin is an anthracycline inhibitor of topoisomerase II which has
recently been shown also to have some activity against topoisomerase I (Foglesong et al. 1992).
Vincristine is a vinca alkaloid, one of a class of drugs which inhibit microtubule assembly and are
particularly effective against rapidly cycling cell populations.
Metastasis is rare after adjuvant therapy, but potentially devastating. There is a need to design less
toxic but equally or more effective regimens with a low risk of mutagenesis which might aid the
development of second malignancies (Tucker et al. 1987). This is a particular problem for some
alkylating agents (such as cyclophosphamide, which has been used in retinoblastoma) and for
etoposide, which is still widely used, although at a dose not expected to cause problems (Shields et al.
1997). Although there is a feeling that more retinal tumours may develop in patients treated with
chemotherapy (C.L. Shields, personal communication), there is as yet no evidence of an increase in
second malignancies in retinoblastoma patients.
Chemosensitivity testing offers a way of testing a large number of agents against tumours. The
ATP-based chemosensitivity assay (ATP-TCA) method does not require the generation of cell lines,
unlike the single previously published study of chemosensitivity testing in retinoblastoma (Chan et al.
1989, 1991). ATP-TCA has already helped to design new regimens for melanoma and breast and
ovarian cancer (Myatt et al. 1997; Kurbacher et al. 1998; Cree and Kurbacher 1997; Cree et al. 1999).
It can also be used to examine the relationship between chemosensitivity and molecular mechanisms
of resistance and sensitivity (Petty et al. 1994; Satherley et al. 2000).
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Materials and Methods
Tumours
Material from ten untreated primary retinoblastomas [2 M:8 F, patient median age 5 months (range
2-36 months)] and one skin metastasis from a primary tumour which was not required for diagnosis
was taken by a histopathologist under sterile conditions and transported to the laboratory in cell culture
medium (DMEM, Sigma, Poole, UK) with antibiotics (100 U/ml penicillin and 100 µg/ml
streptomycin, Gibco BRL, Paisley, UK) at 4°C. Of these samples, only six primary tumours and the
metastasis contained sufficient viable cells.
ATP-TCA
Cells were obtained from the tumours by a very gentle enzymatic dissociation, usually 75 µg/ml
collagenase for 2 h. Viable tumour-derived cells were separated from dead cells and debris by density
centrifugation (Histopaque 1077-1, Sigma), washed, counted and resuspended to 100,000 cells/ml. The
cells were used to set up ATP-TCA plates according to Andreotti et al. (1995).
Briefly, cells from enzymatic digestion of solid tumour were placed in 96-well polypropylene
microplates at 10,000 cells/well with each drug/combination at six doubling dilutions in triplicate from
200% TDC (test drug concentration) to 6.25% TDC. TDCs were 3 µg/ml for cisplatin (CDDP),
0.5 µg/ml for doxorubicin (DOXO), 16 µg/ml for etoposide (ETO), 45 µg/ml for 5-fluorouracil (5-FU),
12 µg/ml for gemcitabine (GEM) and 0.5 µg/ml for vinblastine (VINB).
The plates were then incubated at 37°C in 5% CO2  for 6 days. The degree of cell inhibition at the end
of this period was assessed by measurement of the remaining ATP in comparison with negative
control (no drug, MO) and positive control (maximum inhibitor, MI) rows of 12 wells each. ATP was
extracted from the cells and measured by light output in a microplate luminometer (Berthold
Diagnostic Systems GmbH) after addition of luciferin-luciferase.
Statistics
The percentage inhibition for each drug concentration was calculated as 1- [(Test-MI)/(MO-MI)]*100
using at Excel 97 spreadsheet (Microsoft). For each drug-concentration curve, the area under the curve 
(IndexAUC ), the sum of the inhibition at each concentration (IndexSUM ), the 50% inhibitory
concentration (IC50 ) and the 90% inhibitory concentration (IC90 ) were calculated as previously
described (Cree 1998).
Results
The results show very high sensitivity to single agents, particularly cisplatin, doxorubicin and vinca
alkaloids (Table 1). Of the anti-metabolites tested, 5-FU is relatively disappointing (although still
active), and gemcitabine shows considerable activity consistent with a cytotoxic effect. The shape of
the inhibition curves is interesting. There is a plateau effect with the topoisomerase inhibitors and
vinblastine which is not present with the cisplatin (Fig. 1).
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Table 1. Median values for AUCs, IndexSUM , IC90  and IC50  measured in seven samples. An 
IndexSUM  lower than 300 indicates strong sensitivity in the assay, if >95% inhibition is achieved
Drug IndexAUC IC90 IC50 IndexSUM  
Cisplatin 18,409 (17,626-19,021) 18 (6-72) 4 (3-7) 55 (21-135)
Etoposide 17,939 (17,312-18,399) 48 (5-95) 4 (3-5) 51 (29-99)
Doxorubicin 16,963 (16,697-17,621) 17 (6-94) 4 (3-6) 77 (4-127)
Vinblastine 18,769 (11,739-19,041) 11 (6-293) 4 (3-9) 50 (14-256)
5-FU 14,153 (13,915-14,931) 188 (180-195) 12 (11-13) 218 (212-223)
Gemcitabine 18,386 (15,308-19,287) 20 (6-218) 4 (3-5) 50 (4-148)
VEC 18,806 (17,904-19,207) 6 (6-53) 3 (3-4) 21 (9-78)
VAC 19,033 (18,841-19,225) 6 (-) 3 (-) 17 (7-26)
- 4 -
Fig. 1. Example concentration-inhibition curves showing a plateau effect with the topoisomerase
inhibitors and vinblastine and not with cisplatin in a retinoblastoma
One tumour (Fig. 2) is much more resistant than the others tested, particularly to vinblastine but also to
the topoisomerase inhibitors, which fail to achieve complete kill at any concentration tested. This may
represent overexpression of MDR1 by a proportion of the cells present, and it would be helpful to
check this with immunohistochemistry. 
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Fig. 2. Example concentration-inhibition curves in a resistant retinoblastoma
Of the combinations (VAC and VEC), the VAC regimen looks marginally more active in the more
resistant of the two cases tested to date.
Discussion
These data confirm that retinoblastoma is a rapidly growing malignancy that is very susceptible to
cytotoxic drugs of all types. Based on other tumour types, all these results show significant activity,
although in one case none produced complete ATP inhibition consistent with 100% cell kill. This is
probably academic in most patients. The best dose-response effect was seen with cisplatin, which
probably indicates that platinum is the most effective drug here. The combination with doxorubicin is
likely to be as active as the three-drug combination, and the availability of liposomal preparations
(Doxil/Caelyx) should allow high concentrations to be achieved with a lower risk from MDR+
tumours. Addition of an MDR inhibitor in such patients may be more rational than the use of the
current three-drug regimen incorporating vincristine.
- 6 -
The major risk to survival in these patients is second malignancy. Etoposide use is associated with
haematogenous malignancy and could probably be avoided. The evidence of this study suggests that
doxorubicin is equally effective and it does carry lower risk. However, retinoblastoma patients may
not behave in the same way as those with other malignancies in this regard, given the propensity for
DNA damage to kill rapidly growing cells with Rb mutations.
Drug resistance can occur, and it may arise in several different ways. There is relatively little
information on the relative importance of these mechanisms in retinoblastoma, although as a tumour
with a relatively simple molecular pathogenesis, it may have much to teach oncology in general. The
MDR1/PgP mechanism has been studied in some detail by the Toronto group. Up to 15% of
retinoblastomas express the MDR1 drug efflux protein, and there is evidence that resistant cases
express MRP (Chan et al. 1997). Cyclosporin, an inhibitor of MDR1, can augment the control of
retinoblastoma (Chan et al. 1996), and new inhibitors are in development. Other mechanisms are less
well studied: LRP and MRP are alternative drug efflux pump molecules similar to PgP in their
function; resistance to DNA-damaging agents could be influenced by anti-apoptotic mechanisms. In
retinoblastoma, p53 inactivation and p21Waf1  expression have recently been implicated in resistance
to apoptosis, as could BCL-2 expression, which also occurs in retinoblastoma (Divan et al. 2001).
Although chemotherapy for retinoblastoma is already very successful, several newer cytotoxic drugs
are available with improved side effect profiles and anti-neoplastic activity, including different
mechanisms of action. While it would be difficult to justify clinical trials of the large number of
different options in retinoblastoma, it would be sensible to explore these options pre-clinically and
then conduct a trial against existing practice.
In this study we have shown that ATP-TCA can be used to study the chemosensitivity profile of
retinoblastoma samples despite the small numbers of cells available. The results show that this is a
very chemosensitive tumour, in keeping with its high growth fraction and the observed clinical
efficacy of the drugs tested. Similar data have been produced by Gertjan Kaspers’ group in Amsterdam
with the MTT assay (Kaspers and Veerman, vide infra). This suggests that chemosensitivity testing of
retinoblastoma is feasible and that it can be used to improve understanding of the sensitivity
to/resistance of retinoblastoma to chemotherapy and to develop new drug combinations.
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